Genocea Biosciences Inc. (GNCA) 17.02 $GNCA
Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Elects Not to Pursue Public Offering
Business Wire - Wed Jul 16, 10:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
Genocea Biosciences begins public offering of 3.4m common shares
M2 - Mon Jul 14, 8:55AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday the start of its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Mon Jul 14, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003
Business Wire - Tue Jul 01, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company's immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the final dose, in an analysis of an exploratory endpoint, the mean reduction in genital lesion rate was 42 percent below baseline for the best-performing 30 microgram dose group, indicating that GEN-003 may continue to provide a durable effect on genital lesions beyond the six months previously reported. GEN-003 remained safe and well tolerated. Genocea intends to explore additional dose combinations in its upcoming Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 23, 7:38AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004
Business Wire - Mon Jun 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014.
Genocea Biosciences, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:56PM CDT
Reportbuyer.com has added a new market research report:
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014: Includes 24 Company Profiles
M2 - Thu May 29, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r33tpd/streptococcus) has announced the addition of the "Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Abera Bioscience AB - Beijing Minhai Biotechnology - Chongqing Zhifei Biological Products - ContraFect Corporation - Dainippon Sumitomo Pharma - Eurocine Vaccines - FluGen - Furiex Pharmaceuticals - Genocea Biosciences - GlaxoSmithKline - GlycoVaxyn - Liquidia Technologies, Inc. - Merck & Co - Mucosis - Nabriva Therapeutics - Panacea Biotec Limited - SK Chemicals - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Valneva - Wellstat Vaccines For more information visit http://www.researchandmarkets.com/research/r3...eptococcus
Research and Markets: Gonorrhea - Pipeline Review, H1 2014 Report Featuring Melinta Therapeutics, Cubist Pharmaceuticals & Genocea Biosciences
Business Wire - Wed May 28, 1:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5hwlv/gonorrhea) has announced the addition of the "Gonorrhea - Pipeline Review, H1 2014" report to their offering.
Gonorrhea - Pipeline Review, H1 2014 Report Featuring Melinta Therapeutics, Cubist Pharmaceuticals & Genocea Biosciences
M2 - Wed May 28, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fd665d/gonorrhea) has announced the addition of the "Gonorrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Genocea Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/fd665d/gonorrhea
Genocea to Present at the Needham & Company 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Needham & Company 13th Annual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2014 at 10:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
Genocea Added to Russell 3000(R) and Russell 2000(R) Indices
Business Wire - Tue Apr 01, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000(R) and Russell 2000(R) Indices as part of Russell Investments' first quarter 2014 IPO additions.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Elects Not to Pursue Public Offering
Business Wire - Wed Jul 16, 10:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
Genocea Biosciences begins public offering of 3.4m common shares
M2 - Mon Jul 14, 8:55AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday the start of its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Mon Jul 14, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003
Business Wire - Tue Jul 01, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company's immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the final dose, in an analysis of an exploratory endpoint, the mean reduction in genital lesion rate was 42 percent below baseline for the best-performing 30 microgram dose group, indicating that GEN-003 may continue to provide a durable effect on genital lesions beyond the six months previously reported. GEN-003 remained safe and well tolerated. Genocea intends to explore additional dose combinations in its upcoming Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 23, 7:38AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004
Business Wire - Mon Jun 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014.
Genocea Biosciences, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:56PM CDT
Reportbuyer.com has added a new market research report:
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014: Includes 24 Company Profiles
M2 - Thu May 29, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r33tpd/streptococcus) has announced the addition of the "Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Abera Bioscience AB - Beijing Minhai Biotechnology - Chongqing Zhifei Biological Products - ContraFect Corporation - Dainippon Sumitomo Pharma - Eurocine Vaccines - FluGen - Furiex Pharmaceuticals - Genocea Biosciences - GlaxoSmithKline - GlycoVaxyn - Liquidia Technologies, Inc. - Merck & Co - Mucosis - Nabriva Therapeutics - Panacea Biotec Limited - SK Chemicals - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Valneva - Wellstat Vaccines For more information visit http://www.researchandmarkets.com/research/r3...eptococcus
Research and Markets: Gonorrhea - Pipeline Review, H1 2014 Report Featuring Melinta Therapeutics, Cubist Pharmaceuticals & Genocea Biosciences
Business Wire - Wed May 28, 1:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5hwlv/gonorrhea) has announced the addition of the "Gonorrhea - Pipeline Review, H1 2014" report to their offering.
Gonorrhea - Pipeline Review, H1 2014 Report Featuring Melinta Therapeutics, Cubist Pharmaceuticals & Genocea Biosciences
M2 - Wed May 28, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fd665d/gonorrhea) has announced the addition of the "Gonorrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Genocea Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/fd665d/gonorrhea
Genocea to Present at the Needham & Company 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Needham & Company 13th Annual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2014 at 10:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
Genocea Added to Russell 3000(R) and Russell 2000(R) Indices
Business Wire - Tue Apr 01, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000(R) and Russell 2000(R) Indices as part of Russell Investments' first quarter 2014 IPO additions.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
